FDA Inspection 1236051 — NRG Oncology SDMC
The FDA completed an inspection of NRG Oncology SDMC on Mar 26, 2024 in Pittsburgh, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 26, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Pittsburgh, PA (United States)
Additional Details
Sponsor, Contract Research Organization